SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Rule 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 1 Exiting)*
Sunesis Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
867328502
(CUSIP Number)
12/31/2010
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
| | Rule 13d-1 (b)
|X| Rule 13d-1 (c)
| | Rule 13d-1 (d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Caxton Advantage Life Sciences Fund, L.P.
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
Delaware
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
PN
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Caxton Advantage Venture Partners, L.P.
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
Delaware
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
PN
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Advantage Life Sciences Partners, LLC
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
Delaware
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
CO
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
CHHA LLC
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
Delaware
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
CO
1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Caxton Health Holdings LLC
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
Delaware
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
CO
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Roberts, Eric
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
United States
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
IN
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Leheny, Rachel
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
United States
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
IN
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Caxton Associates LP
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
Delaware
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
0
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
0
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10)Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11)Percent of class represented by amount in Row 9.
.4%
(12)Type of reporting person (see instructions).
IA
(1) Names and I.R.S. Identification Nos.(entities only) of reporting persons.
Kovner, Bruce
(2) Check the appropriate box if a member of a group (see instructions) (a)|_|
(b)|X|
(3) SEC use only.
(4) Citizenship or place of organization.
United States
Number of shares beneficially owned by each reporting person with:
(5) Sole voting power:
(6) Shared voting power:
1,085,898
(7) Sole dispositive power:
(8) Shared dispositive power:
1,085,898
(9) Aggregate amount beneficially owned by each reporting person.
1,085,898
(10) Check if the aggregate amount in Row (9) excludes certain shares |_|
(see instructions).
(11) Percent of class represented by amount in Row 9.
.4%
(12) Type of reporting person (see instructions).
IN
Item 1(a). Name of Issuer:
Sunesis Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
Item 2(a). Name of Person Filing:
(i) Caxton Advantage Life Sciences Fund, L.P. ("Caxton Advantage").
(ii) Caxton Advantage Venture Partners, L.P. ("Caxton Advantage
Venture"). Caxton Advantage Venture is the General Partner
of Caxton Advantage. As a result of the foregoing, Caxton
Advantage Venture may be deemed to have voting and dispositive
power with respect to the securities of the Issuer owned by
Caxton Advantage.
(iii) Advantage Life Sciences Partners, LLC ("Advantage Partners").
Advantage Partners is the General Partner of Caxton Advantage
Venture. As a result of the foregoing, Advantage Partners may be
deemed to have voting and dispositive power with respect to the
securities of the Issuer owned by Caxton Advantage.
(iv) CHHA LLC ("CHHA"). CHHA is the Administrative General Partner of
Caxton Advantage Venture. As a result of the foregoing, CHHA may be
deemed to have voting and dispositive power with respect to the
securities of the Issuer owned by Caxton Advantage.
(v) Caxton Health Holdings LLC ("Caxton Health"). Caxton Health is the
manager of CHHA. As a result of the foregoing, Caxton Health may be
deemed to have voting and dispositive power with respect to the
securities of the Issuer owned by Caxton Advantage.
(vi) Mr. Eric W. Roberts. Mr. Roberts is a Principal of Advantage
Partners and therefore may be deemed to beneficially own the
securities of the Issuer owned by Caxton Advantage.
(vii) Ms. Rachel Leheny. Ms. Leheny is a Principal of Advantage
Partners and therefore may be deemed to beneficially own the
securities of the Issuer owned by Caxton Advantage.
(viii)Caxton Associates LP ("Caxton Associates"). Caxton Associates may be
deemed to have beneficial ownership with respect to the investments of
Caxton Advantage through its ownership of CHHA and Caxton Health.
(ix) Mr. Bruce S. Kovner. Mr. Kovner is the Chairman of Caxton
Associates and the sole shareholder of Caxton Corporation,
the general partner of Caxton Associates. As a result of the foregoing,
Mr. Kovner may be deemed to beneficially own the securities of the
Issuer owned Caxton Advantage.
Item 2(b). Address or Principal Business Office or, If None, Residence:
(i) The address of Caxton Advantage is 500 Park Avenue, New York,
NY 10022.
(ii) The address of Caxton Advantage Venture is 500 Park Avenue,
New York, NY 10022.
(iii) The address of Advantage Partners is 500 Park Avenue, New York,
NY 10022.
(iv) The address of CHHA is 500 Park Avenue, New York, NY 10022.
(v) The address of Caxton Health is 500 Park Avenue,
New York, NY 10022.
(vi) The business address of Mr. Roberts is 500 Park Avenue,
New York, NY 10022.
(vii) The business address of Ms. Leheny is 500 Park Avenue, New York,
NY 10022.
(viii)The address of Caxton Associates is Princeton Plaza, Building 2,
731 Alexander Road, Princeton, NJ 08540.
(ix) The business address of Mr. Kovner is 500 Park Avenue,
New York, NY 10022.
Item 2(c). Citizenship:
(i) Caxton Advantage is a Delaware limited partnership.
(ii) Caxton Advantage Venture is a Delaware limited partnership.
(iii) Advantage Partners is a Delaware limited liability company.
(iv) CHHA is a Delaware limited liability company.
(v) Caxton Health is a Delaware limited liability company.
(vi) Mr. Roberts is a United States citizen.
(vii) Ms. Leheny is a United States citizen.
(viii)Caxton Associates is a Delaware limited partnership.
(ix) Mr. Kovner is a United States citizen.
Item 2(d). Title of Class of Securities:
Common Stock
Item 2(e). CUSIP No.:
867328502
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or
(c), Check Whether the Person Filing is a:
Not Applicable
If this statement is filed pursuant to Rule 13d-1(c), check this box. |X|
Item 4. Ownership
(a) Amount beneficially owned:
(i) The amount of shares of Common Stock beneficially owned by
Caxton Advantage is 1,085,898.
(ii) The amount of shares of Common Stock considered to be
beneficially owned by Caxton Advantage Venture by reason of
its voting and dispositive power with respect to Caxton Advantage
is 1,085,898.
(iii) The amount of shares of Common Stock considered to be beneficially
owned by Advantage Partners by reason of its voting and dispositive
power with respect to Caxton Advantage is 1,085,898.
(iv) The amount of shares of Common Stock considered to be beneficially
owned by CHHA by reason of its voting and dispositive power with
respect to Caxton Advantage is 1,085,898.
(v) The amount of shares of Common Stock considered to be beneficially
owned by Caxton Health by reason of its voting and
dispositive power with respect to Caxton Advantage is 1,085,898.
(vi) The amount of shares of Common Stock considered to be beneficially
owned by Mr. Roberts by reason of the voting and dispositive power
of Advantage Partners is 1,085,898.
(vii) The amount of shares of Common Stock considered to be beneficially
owned by Ms. Leheny by reason of the voting and dispositive power
of Advantage Partners is 1,085,898.
(viii)The amount of shares of Common Stock considered to be beneficially
owned by Caxton Associates by reason of its voting and dispositive
power is 1,085,898.
(ix) Mr. Kovner, by reason of being Chairman of Caxton Associates
and the sole shareholder of Caxton Corporation, the general partner
of Caxton Associates, may also be deemed to beneficially own such
shares.
(b) Percent of class:
(i) Caxton Advantage beneficially owns .4% of the Class
of Common Stock.
(ii) Caxton Advantage Venture may be deemed to beneficially own
.4% of the Class of Common Stock.
(iii) Advantage Partners may be deemed to beneficially own .4% of the
Class of Common Stock.
(iv) CHHA may be deemed to beneficially own .4% of the Class of
Common Stock.
(v) Caxton Health may be deemed to beneficially own .4% of
the Class of Common Stock.
(vi) Mr. Roberts may be deemed to beneficially own .4% of the Class of
Common Stock.
(vii) Ms. Leheny may be deemed to beneficially own .4% of the Class of
Common Stock.
(viii)Caxton Associates may be deemed to beneficially own .4% of the
Class of Common Stock.
(ix) Mr. Kovner may be deemed to beneficially own .4% of the Class of
Common Stock.
(c) Number of shares as to which Caxton Advantage has:
Number of shares as to which Caxton Advantage has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Caxton Advantage Venture has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Advantage Partners has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which CHHA has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Caxton Health has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Mr. Roberts has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Ms. Leheny has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Caxton Associates has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Number of shares as to which Mr. Kovner has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 1,085,898
(iii) Sole power to dispose or to direct the disposition of:
(iv) Shared power to dispose or to direct the disposition
of: 1,085,898
Item 5. Ownership of 5 Percent or Less of a Class.
[X]
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person.
Not Applicable
Item 8. Identification and Classification of Members of the Group.
Not Applicable
Item 9. Notice of Dissolution of Group.
Not Applicable
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date: 2/11/2011 Caxton Advantage Life Sciences
Fund, L.P.
/s/ Eric W. Roberts
Name: Eric W. Roberts
Title: Member, Advantage Life Sciences
Partners, LLC, Managing General
Partner, Caxton Advantage Venture
Partners, L.P., General Partner,
Caxton Advantage Life Sciences Fund,
L.P.
Caxton Advantage Venture
Partners, L.P.
/s/ Eric W. Roberts
Name: Eric W. Roberts
Title: Member, Advantage Life Sciences
Partners, LLC, Managing General
Partner, Caxton Advantage Venture
Partners, L.P.
Advantage Life Sciences Partners, LLC
/s/ Eric W. Roberts
Name: Eric W. Roberts
Title: Member
CHHA LLC
/s/ Scott B. Bernstein
Name: Scott B. Bernstein
Title: Secretary
Caxton Health Holdings LLC
/s/ Scott B. Bernstein
Name: Scott B. Bernstein
Title: Secretary
/s/ Eric W. Roberts
Name: Eric W. Roberts
Title: Member, Advantage Life Sciences
Partners, LLC
/s/ Rachel Leheny
Name: Rachel Leheny
Title: Member, Advantage Life Sciences
Partners, LLC
Caxton Associates LP
Name: Scott B. Bernstein
Title: Secretary
/s/ Bruce S. Kovner
Name: Bruce S. Kovner
Title: signed by Scott B. Bernstein
as Attorney-in-Fact
|
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative other than
an executive officer or general partner of the filing person, evidence of
the representative's authority to sign on behalf of such person shall be
filed with the statement, provided, however, that a power of attorney for
this purpose which is already on file with the Commission may be
incorporated by reference. The name and any title of each person who signs
the statement shall be typed or printed beneath his signature.
ATTENTION: Intentional misstatements or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001). (Secs. 3(b), 13(d)(1), 13(d)(2),
13(d)(5), 13(d)(6), 13(g)(1), 13(g)(2), 13(g)(5), 23, 48 Stat. 882, 894, 901;
sec. 203(a), 49 Stat. 704; sec. 8, 49 Stat. 1379; sec. 10, 78 Stat. 88a; sec.
2, 82 Stat. 454; secs. 1, 2, 84 Stat. 1497; secs. 3, 10, 18, 89 Stat. 97, 119,
155; secs. 202, 203, 91 Stat. 1494, 1498, 1499; (15 U.S.C. 78c(b), 78m(d)(1),
78m(d)(2), 78m(d)(5), 78m(d)(6), 78m(g)(1), 78m(g)(2), 78m(g)(5), 78w)) [43 FR
18499, Apr. 28, 1978, as amended at 43 FR 55756, Nov. 29, 1978; 44 FR 2148,
Jan. 9, 1979; 44 FR 11751, Mar. 2, 1979; 61 FR 49959, Sept. 24, 1996; 62 FR
35340, July 1, 1997; 63 FR 2867, Jan. 16, 1998; 63 FR 15287, Mar. 31, 1998]
Certification
The undersigned hereby certifies that the shares of Sunesis Pharmaceuticals,
Inc. purchased on behalf of Caxton Advantage Life Sciences Fund, L.P. were
not acquired and are not being held for the purpose of or with the effect of
changing or influencing the control of the issuer of such securities and
were not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.
Date: 2/11/2011 /s/ Eric W. Roberts
Eric W. Roberts
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024
